25 Sep 2025 | 5 Mins Read
Lupin shares rise 2% on USFDA HIV drug approval
Flipitmoney
Lupin received tentative US FDA approval for its HIV treatment drug, Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, with estimated annual US sales of $16,237 million. The product is a generic version of Gilead Sciences' Biktarvy and will be manufactured at Lupin's Nagpur facility in India. Lupin shares rose 2.2% to Rs 2,034.95 on BSE.